BR112022011364A2 - Compostos para tratar disautonomia familiar - Google Patents

Compostos para tratar disautonomia familiar

Info

Publication number
BR112022011364A2
BR112022011364A2 BR112022011364A BR112022011364A BR112022011364A2 BR 112022011364 A2 BR112022011364 A2 BR 112022011364A2 BR 112022011364 A BR112022011364 A BR 112022011364A BR 112022011364 A BR112022011364 A BR 112022011364A BR 112022011364 A2 BR112022011364 A2 BR 112022011364A2
Authority
BR
Brazil
Prior art keywords
compounds
dysautonomia
family
treat
present disclosure
Prior art date
Application number
BR112022011364A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhang Nanjing
A Arnold Michael
Dakka Amal
Mitchell Karp Gary
Tuan LUONG Tom
Morrill Christie
Narasimhan Jana
A Naryshkin Nikolai
Turpoff Anthony
Wang Jiashi
Zhang Xiaoyan
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of BR112022011364A2 publication Critical patent/BR112022011364A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
BR112022011364A 2019-12-12 2020-12-07 Compostos para tratar disautonomia familiar BR112022011364A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947049P 2019-12-12 2019-12-12
PCT/US2020/063612 WO2021118929A1 (en) 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
BR112022011364A2 true BR112022011364A2 (pt) 2022-08-23

Family

ID=74046197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011364A BR112022011364A2 (pt) 2019-12-12 2020-12-07 Compostos para tratar disautonomia familiar

Country Status (14)

Country Link
US (1) US20230057568A1 (https=)
EP (1) EP4072677A1 (https=)
JP (2) JP2023506488A (https=)
KR (1) KR20220113700A (https=)
CN (1) CN115209955A (https=)
AU (1) AU2020402717A1 (https=)
BR (1) BR112022011364A2 (https=)
CA (1) CA3160053A1 (https=)
CL (1) CL2022001523A1 (https=)
CO (1) CO2022008195A2 (https=)
IL (1) IL293764A (https=)
MX (1) MX2022007094A (https=)
PE (1) PE20221581A1 (https=)
WO (1) WO2021118929A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
MX2024002887A (es) * 2021-09-07 2024-05-28 Ptc Therapeutics Inc Metodos para tratar enfermedades neurodegenerativas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005007083A2 (en) * 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2611812A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103242341B (zh) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
WO2018151326A1 (ja) * 2017-02-20 2018-08-23 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
SG11202108519TA (en) * 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) * 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
AU2020402717A1 (en) 2022-06-23
WO2021118929A1 (en) 2021-06-17
KR20220113700A (ko) 2022-08-16
JP2025133750A (ja) 2025-09-11
CO2022008195A2 (es) 2022-07-29
CL2022001523A1 (es) 2023-03-31
US20230057568A1 (en) 2023-02-23
JP2023506488A (ja) 2023-02-16
CA3160053A1 (en) 2021-06-17
PE20221581A1 (es) 2022-10-06
MX2022007094A (es) 2022-07-11
IL293764A (en) 2022-08-01
CN115209955A (zh) 2022-10-18
EP4072677A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
MX2021009667A (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
BR112023016299A2 (pt) Composições e métodos para inibir kras
BR112022011364A2 (pt) Compostos para tratar disautonomia familiar
BR112012012815A8 (pt) composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR112021023359A2 (pt) Inibidores de g12c de kras e usos dos mesmos
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
BRPI1006602A2 (pt) composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
BR112019007144A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112018004620A2 (pt) moduladores da expressão de kras
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
BR112014017650A8 (pt) Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson
EP2513343A4 (en) METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
BR112022001161A2 (pt) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
ECSP20082339A (es) Moduladores de la expresión de apol1
BR112012013888A2 (pt) preparados de combinação com antagonista de citocina e corticosteroide
CL2024000250A1 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
FI3270909T3 (fi) Etc1002:ta ja yhtä tai useampaa statiinia käsittäviä kiinteäannoksisia yhdistelmiä kardiovaskulaarisen riskin hoitoon tai ehkäisemiseen
CO2022017705A2 (es) Composiciones y métodos para tratar trastornos asociados a mutaciones de pérdida de función en syngap1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]